Regencell Bioscience Holdings Ltd (RGC) — SEC Filings

Latest SEC filings for Regencell Bioscience Holdings Ltd (RGC), explained in plain English.

Sentiment Overview: 1 bearish, 11 neutral

Recent Filings (12)

• 6-K Filing — 6-K · 2026-03-30T07:18:07-04:00 [neutral]
• 6-K Filing — 6-K · 2026-03-30T07:10:59-04:00 [neutral]
• Regencell Bioscience Files Prospectus Supplement — 424B5 · 2026-03-30T06:41:25-04:00 [neutral] Risk: medium
  Regencell Bioscience Holdings Ltd. filed a prospectus supplement (424B5) on March 30, 2026, related to its registration statement (File No. 333-294722). The fil
• Regencell Bioscience Files F-3ASR Shelf Registration — F-3ASR · 2026-03-30T06:09:11-04:00 [neutral] Risk: medium
  Regencell Bioscience Holdings Ltd. filed an F-3ASR registration statement on March 30, 2026, for an automatic shelf offering. This filing allows the company to
• Regencell Posts $3.58M Loss, Eyes ADHD/ASD TCM Approval — 20-F · 2025-10-31T00:00:00.000Z [bearish] Risk: high
  Regencell Bioscience Holdings Ltd (RGC) reported net losses of $3.58 million for the fiscal year ended June 30, 2025, following a $4.36 million net loss in fisc
• Regencell Bioscience Files Interim Financials for Dec 31, 2024 — 6-K · 2025-06-30T00:00:00.000Z [neutral] Risk: low
  Regencell Bioscience Holdings Limited has filed a Form 6-K on June 30, 2025, to furnish its unaudited condensed consolidated interim balance sheets and statemen
• Regencell Bioscience Completes 38-for-1 Stock Split — 6-K · 2025-06-17T00:00:00.000Z [neutral] Risk: low
  Regencell Bioscience Holdings Limited announced a 38-for-one forward stock split on June 2, 2025, effective for shareholders of record on that date. This split
• Regencell Bioscience Announces 38-for-1 Stock Split — 6-K · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  Regencell Bioscience Holdings Limited announced on June 2, 2025, that its board of directors approved a 38-for-one forward stock split, effective for shareholde
• Regencell Extends Director/Employee Stock Lock-up to April 2026 — 6-K · 2025-01-15T00:00:00.000Z [neutral] Risk: low
  Regencell Bioscience Holdings Limited announced on January 15, 2025, that all directors and employees who received stock options have agreed to an extended lock
• Regencell Bioscience Files 2024 Annual Report — 20-F · 2024-10-25T00:00:00.000Z [neutral] Risk: low
  Regencell Bioscience Holdings Ltd. filed its annual report on Form 20-F for the fiscal year ended June 30, 2024. The company, incorporated in the Cayman Islands
• Regencell Bioscience Files Interim Financials — 6-K · 2024-06-20T00:00:00.000Z [neutral] Risk: low
  Regencell Bioscience Holdings Limited has filed a Form 6-K on June 20, 2024, to furnish its unaudited condensed consolidated interim financial statements for th
• Regencell Bioscience: Dr. Chao Resigns, COO Chung Appointed Director — 6-K · 2024-01-02T00:00:00.000Z [neutral]
  Regencell Bioscience Holdings Limited announced a change in its board of directors. Dr. Yi-Chung Chao resigned as a director for personal reasons, effective Dec